Advances in the medical device industry have led to a substantial increase in developmental complexity, clinical trial conduct, and stringency of regulatory review, causing sponsors to rely on the technical and regulatory affairs management expertise of CROs Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CRO Market (2nd Edition), 2020-2030”.The report features an extensive study of the current market landscape and future opportunities of contract research service providers focused on medical devices.The study also features an in-depth analysis, highlighting the capabilities of the various stakeholders engaged in this domain, across different regions of the globe.In addition to other elements, the study includes:A detailed review of the overall landscape of medical device CROs.An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, and Asia-Pacific and rest of the world.Elaborate profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices.An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers engaged in this domainA competitive benchmarking, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of service portfolio).A detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices.A detailed analysis of the mergers and acquisitions that have taken place in this domain during the period 2015-2020.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers.A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.An elaborate discussion on the future opportunities / trends for the medical device outsourcing market that are likely to influence the growth of this domain over the coming years.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Phase of Development ClinicalPreclinical Types of Preclinical Services OfferedBiocompatibility testingSterility and microbiology testingMaterial characterization and analytical servicesOthers Types of Clinical Services OfferedClinical trial managementData managementRegulatory affairs managementConsultingOthers Device ClassClass I medical devicesClass II medical devicesClass III medical devices Target Therapeutic AreaCNS disordersCardiovascular disordersOncological disordersBone disordersRespiratory disordersPain management disordersOphthalmic disordersPsychological disordersMetabolic disordersOthers Key Geographical RegionsNorth AmericaEuropeAsia-PacificRest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companiesLajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial)Christopher Rupp (Vice President of Global Marketing and Commercial Operations, NAMSA)Christian Wolflehner (General Manager, CW Research & Management)Troy Mccall (Chief Operating Officer, CROMSOURCE)Nazish Urooj (Senior manager, Medical & Clinical Operations, Metrics Research)Omprakash (Technical Director and Partner, Vyomus Consulting)Tania Persson (Director of Business Development, A+ Science)Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO) Key companies covered in the reportAvania (formerly known as Factory CRO)Charles River LaboratoriesClinlogixCROMSOURCECSSi LifeSciences™Eurofins Medical Device TestinggenaeIMARC ResearchIQVIAMedpaceNAMSAQserve GroupRegulatory and Clinical Research Institute (now a part of Covance)WuXi AppTec For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html Other Recent OfferingsContract Regulatory Affairs Management Market for Medical Devices, 2019-2030Medical Device Labels Manufacturing Market, 2019 - 2030Medical Device Contract Manufacturing Market, 2019-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Yesterday, we reported that Intel officially announced that its CEO, Bob Swan, will be leaving office in February this year. He will be replaced by ... The post Intel will make chips better than Apple’s PC chips – Intel’s new CEO appeared first on Gizchina.com.
9
CEO says he is 'truly sorry for painful but necessary' cuts Dropbox is decimating its workforce, firing 11 per cent of staff in an effort to become “a more efficient and nimble” company, its CEO announced on Wednesday.…
10
Agencies like Boomn, Homestead Studios and Freelance Crew, among others, expect to debut new DTC brands during Q1 this year. The post ‘People won’t question our ability’: Why performance marketing agencies want to create their own DTC brands appeared first on Digiday.
2
Jen Wong, Reddit chief operating officer and CES 2021 panelist, discusses the changes this past year has brought to Reddit, and what 2021 has in store.
4
Cruise AV, the GM-backed autonomous vehicle startup aiming to replace cabs with driverless electric pods, has brought in the big guns as it readies for a broad robotaxi rollout. Gil West, former Delta Air Lines Chief Operating Officer, has joined Cruise as its new COO, where he’ll be responsible for figuring out how to launch autonomy at scale. “Large robotaxi … Continue reading
9
With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism.In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade.In addition to other elements, the study includes:A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditionsElaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Source of Stem CellAllogeneicAutologous Origin of Stem CellAdultEmbryonic Type of Stem CellHematopoieticMesenchymalProgenitorOthers Lineage of Stem CellAdipose TissueBone MarrowCord BloodOthers Route of AdministrationIntraarticularIntracoronaryIntramuscularIntramyocardialIntrathecalIntravenousSurgical ImplantationsOthers Therapeutic AreaAutoimmune / Inflammatory DisorderCardiovascular DisordersMetabolic DisorderMusculoskeletal DisordersOncological DisordersNeurological DisordersOphthalmic DisordersOthers End UsersAmbulatory Surgery CentersHospitalsSpecialty Clinics Key Geographical RegionsNorth AmericaEuropeAsia-Pacific and Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companiesWilliam L Rust (Founder and Chief Executive Officer, Seraxis)Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)Kikuo Yasui (Director and Chief Operating Officer, Heartseed)Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)Gilles Devillers (President, Bio Elpida)Fiona Bellot (Business Development Manager, Roslin Cell Therapies)David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) Key companies covered in the reportAnterogenAthersysCHABiotechCytopeuticsHope BiosciencesJapan Regenerative MedicineLineage Cell TherapeuticsOrchard TherapeuticsOsiris TherapeuticsPluristem TherapeuticsPromithera BiosciencesRegenexxStempeutics ResearchSCM Life SciencesTICEBA For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/ Other Recent OfferingsStem Cell Therapy Contract Manufacturing Market, 2019-2030Antibody Drug Conjugates Market (5th Edition), 2019-2030Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological SolutionsGlobal T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
Comcast Cable consumer president Dana Strong will take over as the new group chief executive of Sky this year after longtime holder of the post Jeremy Darroch tendered his resignation.
4
They just seem to succeed in everything that they do (and rake in a lot of money).No they are not sent by alien civilizations and they also fail in some of their endeavors.They just seem to have a little of every talent needed, have 101% gusto to do what they do, and have a laser-guided focus to achieve their goals.In the early days of their companies, be it in a garage or from their dorm rooms, these successful startup founders wore a lot of hats.They are like the Energizer bunny doing the jobs of the chief operating officer, doing product design, recruiting people, and even managing PR.It is crazy how they managed to do all the duties and through their unique talents, they achieved success.Here are some of those characteristics that help them go on with their venture, succeed with it, and make it grow:LeadershipThis is the most crucial characteristic of a successful startuptechpreneur.If you want to get to the top, you must know how to blend with the startup culture and be creative to get the funding you need.Your ideas are your dreams but this dream should be pliable enough so you can help shape solutions to the problems of consumers.Kevin Systrom is the co-founder of Burbn which is the predecessor of Instagram.As a startup founder, you must learn how to structure your work so everyone knows his or her roles andresponsibilities while you focus on yours.Discipline will help you find out what the problem is.
Cook made 256 times as much as "typical" Apple employees compared to 200 times as much in the previous year, as executive pay continues to climb.
5
The newly raised funds will be used to expand company's operations throughout India in the next 12 months.
4
"It was easier to sell 'flight proven' to customers than it was to sell Falcons."
4
With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism.In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade.In addition to other elements, the study includes:A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditionsElaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Source of Stem CellAllogeneicAutologous Origin of Stem CellAdultEmbryonic Type of Stem CellHematopoieticMesenchymalProgenitorOthers Lineage of Stem CellAdipose TissueBone MarrowCord BloodOthers Route of AdministrationIntraarticularIntracoronaryIntramuscularIntramyocardialIntrathecalIntravenousSurgical ImplantationsOthers Therapeutic AreaAutoimmune / Inflammatory DisorderCardiovascular DisordersMetabolic DisorderMusculoskeletal DisordersOncological DisordersNeurological DisordersOphthalmic DisordersOthers End UsersAmbulatory Surgery CentersHospitalsSpecialty Clinics Key Geographical RegionsNorth AmericaEuropeAsia-Pacific and Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companiesWilliam L Rust (Founder and Chief Executive Officer, Seraxis)Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)Kikuo Yasui (Director and Chief Operating Officer, Heartseed)Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)Gilles Devillers (President, Bio Elpida)Fiona Bellot (Business Development Manager, Roslin Cell Therapies)David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) Key companies covered in the reportAnterogenAthersysCHABiotechCytopeuticsHope BiosciencesJapan Regenerative MedicineLineage Cell TherapeuticsOrchard TherapeuticsOsiris TherapeuticsPluristem TherapeuticsPromithera BiosciencesRegenexxStempeutics ResearchSCM Life SciencesTICEBA For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/ Other Recent OfferingsStem Cell Therapy Contract Manufacturing Market, 2019-2030Antibody Drug Conjugates Market (5th Edition), 2019-2030Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological SolutionsGlobal T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
1
Investment platform CoAssets loaned millions of dollars from investors to plow into projects. It’s now unable to pay them back.
5
Advances in the medical device industry have led to a substantial increase in developmental complexity, clinical trial conduct, and stringency of regulatory review, causing sponsors to rely on the technical and regulatory affairs management expertise of CROs Roots Analysis is pleased to announce the publication of its recent study, titled, “Medical Device CRO Market (2nd Edition), 2020-2030”.The report features an extensive study of the current market landscape and future opportunities of contract research service providers focused on medical devices.The study also features an in-depth analysis, highlighting the capabilities of the various stakeholders engaged in this domain, across different regions of the globe.In addition to other elements, the study includes:A detailed review of the overall landscape of medical device CROs.An elaborate discussion on the various guidelines established by major regulatory bodies for medical device approval across North America, Europe, and Asia-Pacific and rest of the world.Elaborate profiles of key players that specialize in offering services for both clinical and preclinical stage development of medical devices.An analysis highlighting the key performance indicators used by sponsor companies to evaluate service providers engaged in this domainA competitive benchmarking, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective peer groups.A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of service portfolio).A detailed geographical clinical trial analysis of ongoing and planned studies related to medical devices.A detailed analysis of the mergers and acquisitions that have taken place in this domain during the period 2015-2020.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract research services to medical device developers.A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution.An elaborate discussion on the future opportunities / trends for the medical device outsourcing market that are likely to influence the growth of this domain over the coming years.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Phase of Development ClinicalPreclinical Types of Preclinical Services OfferedBiocompatibility testingSterility and microbiology testingMaterial characterization and analytical servicesOthers Types of Clinical Services OfferedClinical trial managementData managementRegulatory affairs managementConsultingOthers Device ClassClass I medical devicesClass II medical devicesClass III medical devices Target Therapeutic AreaCNS disordersCardiovascular disordersOncological disordersBone disordersRespiratory disordersPain management disordersOphthalmic disordersPsychological disordersMetabolic disordersOthers Key Geographical RegionsNorth AmericaEuropeAsia-PacificRest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companiesLajos Sarosi (Chief Executive Officer and Co-founder, HungaroTrial)Christopher Rupp (Vice President of Global Marketing and Commercial Operations, NAMSA)Christian Wolflehner (General Manager, CW Research & Management)Troy Mccall (Chief Operating Officer, CROMSOURCE)Nazish Urooj (Senior manager, Medical & Clinical Operations, Metrics Research)Omprakash (Technical Director and Partner, Vyomus Consulting)Tania Persson (Director of Business Development, A+ Science)Alexa Foltin-Mertgen (Business Development Manager, AtoZ-CRO) Key companies covered in the reportAvania (formerly known as Factory CRO)Charles River LaboratoriesClinlogixCROMSOURCECSSi LifeSciences™Eurofins Medical Device TestinggenaeIMARC ResearchIQVIAMedpaceNAMSAQserve GroupRegulatory and Clinical Research Institute (now a part of Covance)WuXi AppTec For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/medical-device-cros-market/226.html Other Recent OfferingsContract Regulatory Affairs Management Market for Medical Devices, 2019-2030Medical Device Labels Manufacturing Market, 2019 - 2030Medical Device Contract Manufacturing Market, 2019-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
1
"It was a planning error, and I am responsible," said General Gustave Perna, the chief operating officer of Operation Warp Speed.
5
Business Insider spoke to three private aviation executives who revealed what they're looking for when they hire pilots.
6
 Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contract service providers Roots Analysis is pleased to announce the publication of its recent study, titled, “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030.” The report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of HPAPIs and cytotoxic drugs.The study also features a detailed analysis of the key drivers and trends related to this evolving domain.In addition to other elements, the study includes:A detailed assessment of the current market landscape of companies offering contract services for manufacturing HPAPIs and cytotoxic drugs.A competitiveness analysis of HPAPI and cytotoxic drugs contract manufacturers, featuring insightful representations.Detailed profiles of leading contract manufacturers of HPAPI and cytotoxic drugs (shortlisted on the basis of proprietary criterion).An analysis of the partnerships that have been established in this domain, in the recent past.An analysis of the various expansion initiatives undertaken by the players in this domain.An estimate of the overall, installed capacity for manufacturing HPAPIs and cytotoxic drugs based on data reported by industry stakeholders in the public domain.A qualitative analysis to decide whether to manufacture the potent products in-house or engage the services of a CMO.A discussion on affiliated trends, key drivers and challenges which are likely to impact the industry’s evolution.A case study on the antibody drug conjugates (ADCs) manufacturing market, highlighting a list of contract service providers and in-house manufacturers in this domain.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Type of ProductHPAPIsHighly Potent Finished Dosage Forms Company SizeSmall-sizedMid-sizedLarge / Very Large Scale of OperationPreclinical / ClinicalCommercial Type of Pharmacological MoleculeSmall MoleculesBiologics Type of Highly Potent Finished Dosage FormInjectablesOral SolidsCreamsOthersKey geographical regionsNorth AmericaEuropeAsia PacificRest of the World The report includes detailed transcripts of discussions held with the following senior level representatives of stakeholder companies:Antonella Mancuso (Vice President and Chief Operating Officer, BSP Pharmaceuticals) and Maria Elena Guadagno (Business Director, BSP Pharmaceuticals)Klaus Hellerbrand (Managing Director, ProJect Pharmaceutics)Kevin Rosenthal (Business Head, Formulations and Finished Products, Alphora Research)Jennifer L Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)Roberto Margarita (Business Development Director, CordenPharma)Allison Vavala (Senior Manager, Business Development, Helsinn)Mark Wright (Site Head, Piramal Healthcare)Javier E. Aznárez Araiz (Business Development Technician, Idifarma) Key companies covered in the reportAbbVie Contract ManufacturingCARBOGEN AMCISCatalentEvonikFormosa LaboratoriesIntasLonzaMabPlexPfizer CentreOne For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html   Other Recent OfferingsAntibody Contract Manufacturing Market, 2020 – 2030Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030Biopharma Contract Manufacturing Market (3rd Edition), 2019 – 2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]  
 Roots Analysis has done a detailed study on Endocannabinoid System Targeted Therapeutics Market, 2020-2030“ covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this link Key Market InsightsMore than 65 industry players across the world are presently engaged in evaluating the clinical applications of over180 cannabinoid-derivatives that target the human endocannabinoid signaling systemThe pipeline features a variety of marketed / clinical stage therapies, being investigated for a wide range of target disease indications and designed for administration via different routesThe geographical landscape of this industry is likely to evolve in the next few years as federal authorities legalize the use of medical cannabis across multiple countriesDespite the associated stigma, many organizations have extended financial support to aid research efforts in this domain; the focus is on understanding the clinical benefits of endocannabinoid signaling in different diseasesThe growing interest in this field is also reflected by the 170+ partnerships that have been signed in the last five years, involving both international and indigenous stakeholders, across different geographical marketplacesPresently, North American companies seem to be consolidating their presence indigenously, mostly through strategic acquisitions; key value drivers behind such deals include product and geographical expansionFuture market size, based on revenue generation potential of marketed and late stage therapies, is anticipated to be distributed across a variety of therapeutic areas, target receptors and key geographical regions For more information, please visit “Endocannabinoid System Targeted Therapeutics Market, 2020-2030.“ Table of Contents  PREFACE1.1.Prominent Program Officers: Analysis by Number of Grants6.3.15.Global Endocannabinoid Targeted Therapeutics Market, 2020-203010.4.Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2020-203010.7.3.Interview Transcript: Steeve Néron, Chief Operating Officer 12.5      Vireo Health     12.5.1.
 With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism.In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.The  report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade.In addition to other elements, the study includes:A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditionsElaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Source of Stem CellAllogeneicAutologous Origin of Stem CellAdultEmbryonic Type of Stem CellHematopoieticMesenchymalProgenitorOthers Lineage of Stem CellAdipose TissueBone MarrowCord BloodOthers Route of AdministrationIntraarticularIntracoronaryIntramuscularIntramyocardialIntrathecalIntravenousSurgical ImplantationsOthers Therapeutic AreaAutoimmune / Inflammatory DisorderCardiovascular DisordersMetabolic DisorderMusculoskeletal DisordersOncological DisordersNeurological DisordersOphthalmic DisordersOthers End UsersAmbulatory Surgery CentersHospitalsSpecialty Clinics Key Geographical RegionsNorth AmericaEuropeAsia-Pacific and Rest of the World Transcripts of interviews held with the following senior level representatives of stakeholder companiesWilliam L Rust (Founder and Chief Executive Officer, Seraxis)Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)Kikuo Yasui (Director and Chief Operating Officer, Heartseed)Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)Gilles Devillers (President, Bio Elpida)Fiona Bellot (Business Development Manager, Roslin Cell Therapies)David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) Key companies covered in the reportAnterogenAthersysCHABiotechCytopeuticsHope BiosciencesJapan Regenerative MedicineLineage Cell TherapeuticsOrchard TherapeuticsOsiris TherapeuticsPluristem TherapeuticsPromithera BiosciencesRegenexxStempeutics ResearchSCM Life SciencesTICEBA For more information please click on the following link:https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/ Other Recent OfferingsStem Cell Therapy Contract Manufacturing Market, 2019-2030Antibody Drug Conjugates Market (5th Edition), 2019-2030Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological SolutionsGlobal T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
More

Top